Levophacetoperane

Source: Wikipedia, the free encyclopedia.
Levophacetoperane
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[1]
  • In general: ℞ (Prescription only)
Identifiers
  • [(R)-phenyl-[(2R)-piperidin-2-yl]methyl] acetate
JSmol)
  • CC(=O)O[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2
  • InChI=1S/C14H19NO2/c1-11(16)17-14(12-7-3-2-4-8-12)13-9-5-6-10-15-13/h2-4,7-8,13-15H,5-6,9-10H2,1H3/t13-,14-/m1/s1
  • Key:BKPLVPRTTWIDNL-ZIAGYGMSSA-N
  (verify)

Levophacetoperane (Lidépran, Phacétoperane) is a

psychostimulant developed by Rhône-Poulenc in the 1950s.[2] The drug has been used as an antidepressant and anorectic.[3][4] It is the reverse ester of methylphenidate
.

See also

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ US 2928835, Marie JN, Michel JR, "New esters", published 15 March 1960, assigned to Rhône-Poulenc 
  3. PMID 239015
    .
  4. ^ US 20150038533, Konofal E, Figadere B, "Phacetoperane for the treatment of attention-deficit hyperactivity disorder", published 5 February 2015, assigned to Assistance Publique – Hôpitaux de Paris